# US 2020/0390772 A1 · Dual clk/cdk1 inhibitors for cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390772 A1
- Document ID: US20200390772A1
- Status: Published application
- Kind: A1
- Application number: 16/886,290
- Filed: 2020-05-28
- Published: 2020-12-17
- Earliest claimed: 2016-09-30
- Assignees: SRI International
- Applicants: Sri International
- Inventors: Thomas R. Webb; Jaehyeon Park; Chandraiah Lagisetti
- Web page: https://patentgrep.com/patent/US20200390772A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 35/00: Antineoplastic agents
- C07D 473/16: two nitrogen atoms
- C07D 473/32: Nitrogen atom
- C07D 487/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The disclosure generally relates to substituted purine analogs that are dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDK1 kinases. These compounds may be useful in the treatment of germ-line mutations of the spliceosome leading to the development of cancers and other human disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A compound having a structure represented by a formula selected from:
wherein n is selected from 1 and 2;
wherein each of Q1 and Q2 is independently selected from N and CH;
wherein R1 is selected from —OH, —NHR4, —(C1-C4 alkyl)OH, and —(C1-C4 alkyl)NHR4;
wherein R4, when present, is selected from hydrogen and C1-C4 alkyl;
wherein each occurrence of each of R2a, R2b, R2c, R2d, R2e, and R2f is independently selected from hydrogen and C1-C8 alkyl;
wherein R3 is selected from ethyl and isopropyl; and
wherein Ar1 is selected from monocyclic aryl, 6-membered heteroaryl, and bicyclic heteroaryl, and is substituted with 0-4 groups independently selected from halogen, —OH, —NH2, —CN, —NO2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, —NHC(O)(C1-C4 alkyl), C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino,
or a pharmaceutically acceptable derivative thereof.

### Claim 22 (depends on 21)

The compound of claim 21, wherein n is 2.

### Claim 23 (depends on 21)

The compound of claim 21, wherein Q2 is N.

### Claim 24 (depends on 21)

The compound of claim 21, wherein R1 is —NHR4.

### Claim 25 (depends on 21)

The compound of claim 21, wherein each of R2a, R2b, R2c, R2d, R2e, and R2f is hydrogen.

### Claim 26 (depends on 21)

The compound of claim 21, wherein Ar1 is a moiety having a structure represented by a formula:
wherein Z1 is selected from CH and N; and
wherein Z2 is selected from CH2 and NH.

### Claim 27 (depends on 21)

The compound of claim 21, wherein the compound has a structure represented by a formula selected from:

### Claim 28 (depends on 21)

The compound of claim 21, wherein the compound is selected from:

### Claim 29 (depends on 21)

The compound of claim 21, wherein the compound is selected from:

### Claim 30 (depends on 21)

A pharmaceutical composition comprising an effective amount of at least one compound of claim 21 and a pharmaceutically acceptable carrier.

### Claim 31

A method for treating a disorder having an aberrant germ-like mutation in a subject, the method comprising the step of administering to the subject an effective amount of at least one compound that inhibits CLK2 and/or CDK1.

### Claim 32 (depends on 31)

The method of claim 31, wherein the compound has a structure represented by a formula selected from:
wherein n is selected from 1 and 2;
wherein each of Q1 and Q2 is independently selected from N and CH;
wherein R1 is selected from —OH, —NHR4, —(C1-C4 alkyl)OH, and —(C1-C4 alkyl)NHR4;
wherein R4, when present, is selected from hydrogen and C1-C4 alkyl;
wherein each occurrence of each of R2a, R2b, R2c, R2d, R2e, and R2f is independently selected from hydrogen and C1-C8 alkyl;
wherein R3 is selected from ethyl and isopropyl; and
wherein Ar1 is selected from monocyclic aryl, 6-membered heteroaryl, and bicyclic heteroaryl, and is substituted with 0-4 groups independently selected from halogen, —OH, —NH2, —CN, —NO2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, —NHC(O)(C1-C4 alkyl), C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino,
or a pharmaceutically acceptable derivative thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein Ar1 is a moiety having a structure represented by a formula:
wherein Z1 is selected from CH and N; and
wherein Z2 is selected from CH2 and NH.

### Claim 34 (depends on 32)

The method of claim 32, wherein the compound has a structure represented by a formula selected from:

### Claim 35 (depends on 31)

The method of claim 31, wherein the disorder is selected from retinitis Pigmentosa, microcephalic osteodysplastic primordial dwarfism (MOPD) type 1, and cancer.

### Claim 36 (depends on 35)

The method of claim 35, wherein the cancer is selected from chronic lymphocytic leukemia (CLL), myelodysplasia, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), breast cancer, lung adenosarcoma, and uveal melanoma.

### Claim 37 (depends on 31)

The method of claim 31, wherein the compound inhibits CLK2 activity.

### Claim 38 (depends on 31)

The method of claim 31, wherein the compound inhibits CDK1 activity.

### Claim 39 (depends on 31)

The method of claim 31, wherein the compound inhibits CLK2 and CDK1 activity.

### Claim 40 (depends on 31)

The method of claim 31, wherein the effective amount is a therapeutically effective amount.
